U.S. Stock Market Midday Update

Indaptus Therapeutics fell 10.14%. There have been no significant news recently; trading is active with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news

Stocks with High Trading Volume in the Industry

Moderna rose 8.51%, with a trading volume of $9.572 billion. Based on recent key news:

1. On August 21, Moderna's mRNA cancer therapy, developed in collaboration with Merck, achieved positive results in a Phase III clinical trial for melanoma, driving the stock price up. Goldman Sachs raised Merck's target price to $160, maintaining a buy rating. Source: Zhitong Finance

2. On August 20, Moderna's stock surged due to positive data from its mRNA cancer vaccine, with short positions reaching as high as 13.7%, leading to a short squeeze that propelled the stock price. UBS data showed that clients sold a record $44 million worth of Moderna stock on Wednesday. Source: Bloomberg

3. On August 19, the personalized mRNA cancer vaccine jointly developed by Moderna and Merck achieved positive results in a Phase III clinical trial, significantly reducing the risk of postoperative recurrence in melanoma patients. The Nasdaq Biotechnology Index rose over 5%. Source: Wall Street Insight. The biotechnology sector has performed strongly recently, with significant capital inflows.

AbbVie rose 1.43%. Based on recent key news:

1. On August 19, AbbVie's Executive Vice President and Chief Business Strategy Officer Nicholas Donoghoe exercised stock options and sold 32,710 shares, raising market concerns about executive confidence in the company, leading to stock price volatility.

2. On August 21, AbbVie presented the latest clinical data for its innovative drug ABBV-706 at the World Lung Cancer Conference, showing significant efficacy and boosting market confidence.

3. On August 21, Piper Sandler maintained AbbVie's rating at "Overweight," further enhancing investor confidence in the company. Competition in the innovative drug industry is intensifying, with high R&D investments.

Amgen rose 1.65%, with increased trading volume. Based on recent key news:

1. On August 21, Piper Sandler raised Amgen's target price from $427 to $457, maintaining an "Overweight" rating. This move reflects market confidence in Amgen's future growth, driving the stock price up.

2. On August 21, Amgen reached a historical high of $435.26 during trading. Several institutions raised their target prices, with BMO setting a target price of $450 and Argus raising its target price from $375 to $460, further boosting market confidence.

3. On August 21, the U.S. Federal Trade Commission conducted an antitrust review of Amgen's patent acquisition deal, which may impact the company's future strategy, but did not have a significant negative effect on the stock price The biotechnology industry has recently shown strong performance, with significant capital inflows.

Stocks ranked at the top of the industry market capitalization

Gilead Sciences rose by 2.26%. Based on recent key news:

1. On August 20, Gilead Sciences' stock rose for seven consecutive trading days, mainly benefiting from the continued growth of its core HIV product portfolio. In the second quarter, HIV sales increased by 12% year-on-year to $5.69 billion, driving the company's overall revenue growth of 10.2% to $7.8 billion, exceeding market expectations.

2. On August 19, Gilead Sciences' Chief Communications and Corporate Affairs Officer Johanna Mercier exercised stock options to purchase 25,000 shares and sold 28,000 shares on the same day at a price of approximately $137.37 to $138.04 per share. This insider trading activity may have a short-term impact on market sentiment.

3. On August 19, Gilead Sciences' cell therapy business revenue decreased by 12% year-on-year, mainly due to intensified market competition and setbacks in collaborative development, which pose a threat to its tumor diversification plan. The strong growth of the HIV product portfolio has driven the stock price up